Technion Research & Development Foundation Limited

Teva Pharmaceutical Industries Limited

Tel Hashomer Medical Research Infrastructure and Services Ltd.

Roy Noy

Kfir Oved

Yoram Reiter

Eran Eden

Martin Akerman

Michal Besser

A method of determining responsiveness to cancer treatment is disclosed. The method comprises analyzing a frequency of tumor infiltrating lymphocytes (TILs) having a CD8CD28CD152signature in a sample of the subject, wherein a frequency of TILs having the CD8CD28CD152signature above a predetermined level is indicative of a positive responsiveness to cancer treatment. Other signatures reflecting responsiveness to cancer treatment are also disclosed. In addition, methods of treating cancer based on these signatures are also disclosed.

Method of predicting responsiveness to autologous adoptive cell transfer therapy

This invention provides fusion proteins comprising consecutive amino acids which beginning at the amino terminus of the protein correspond to consecutive amino acids present in (i) a cytomegalovirus human MHC-restricted peptide, (ii) a first peptide linker, (iii) a human &#x3b2;-2 microglobulin, (iv) a second peptide linker, (v) a HLA-A2 chain of a human MHC class I molecule, (vi) a third peptide linker, (vii) a variable region from a heavy chain of a scFv fragment of an antibody, and (viii) a variable region from a light chain of such scFv fragment, wherein the consecutive amino acids which correspond to (vii) and (viii) are bound together directly by a peptide bond or by consecutive amino acids which correspond to a fourth peptide linker, wherein the antibody from which the scFv fragment is derived specifically binds to mesothelin. This invention provides nucleic acid constructs encoding same, processes for producing same, compositions, and uses thereof.

Fusion proteins, uses thereof and processes for producing same

Growing community of inventors

Savyon, Israel

Roy Noy